Stock Analiz

Daxor Corp. DXR

Medical/Dental Instruments · data as of November 13, 2026

$8.48Market cap $50M
Open the interactive analysis →

Daxor Corp. (DXR) is a healthcare company listed in the US with a market value of about $50M. In fiscal year 2011 it had revenue of $1M and net income of -$7M, a net margin of -496.8%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -11%.

About Daxor

Daxor is listed in the US and classified in medical/dental instruments. It was profitable in 1 of the last 2 years in our data. It spends 187% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns2/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Pays a dividend
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S34.2
P/B1.4
EV/EBITDA—
PEG—
Dividend yield2.13%
FCF yield-13.4%
Shareholder yield2.6%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-496.8%
ROIC (5-yr avg.)-11.0%
Profitable years (of last 10)1
Years paying a dividend2

Financials, last 2 years

Fiscal year20112010
Revenue$1M—
Net income-$7M$5M
Free cash flow-$7M-$6M
EPS (diluted)$-1.70$1.17
Net margin-496.8%—
ROIC-12.5%-9.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Daxor pay a dividend?

Yes. The dividend yield is about 2.13%, and it has paid dividends for 2 years in our data.

Is Daxor a good stock to buy?

We do not give buy or sell advice. Daxor scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.